Trials / Unknown
UnknownNCT04963608
RWS of Inetetamab HER2 Positive Advanced Breast Cancer
Real World Study of Inetetamab HER2 Positive Advanced Breast Cancer
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- Zhiyong Yu · Academic / Other
- Sex
- Female
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This non-Interventional study will describe and analyze the clinical use of Inetetamab in clinical practice in the treatment of HER2 positive advanced breast cancer in the real world.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Inetetamab | 8mg/kg iv day 1 followed by 6mg/kg iv day 1, cycled every 21 days |
Timeline
- Start date
- 2021-07-01
- Primary completion
- 2021-12-01
- Completion
- 2021-12-01
- First posted
- 2021-07-15
- Last updated
- 2021-07-15
Source: ClinicalTrials.gov record NCT04963608. Inclusion in this directory is not an endorsement.